HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Newby, L. K. Articles by Ohman, E. M. Search for Related Content PubMed Articles by Newby, L. K. Articles by Ohman, E. M.

Troponin: an important prognostic marker and risk-stratification tool in non–ST-segment elevation acute coronary syndromes

L. Kristin Newby, MD, FACC^*, Britta U. Goldmann, MD and E. Magnus Ohman, MD, FACC^,*

^* Duke Clinical Research Institute, Durham, North Carolina, USA
University Hospital Eppendorf, Hamburg, Germany
University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA

View larger version (15K): [in a new window]   Figure 1 Odds ratios with 95% confidence interval for death or myocardial infarction among troponin-negative and troponin-positive patients and for interaction of troponin status with treatment effect for Platelet Receptor inhibition for Ischemic Syndrome Management (PRISM), Chimeric c7E3 AntiPlatelet Therapy in Unstable REfractory angina (CAPTURE), Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network (PARAGON-B), and combined trials. Values to the left of 1.0 indicate a benefit of glycoprotein IIb/IIIa inhibition. TnT = troponin T. Newby LK, Ohman EM, Christenson RH, et al. Benefit of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes and troponin T-positive status: the PARAGON-B Troponin T Substudy. Circulation 2001;103:2891–6. Reproduced with permission from Lippincott, Williams and Wilkins.